表皮生长因子受体酪氨酸激酶抑制剂单药治疗应仍是晚期表皮生长因子受体突变型非小细胞肺癌的标准一线治疗方案。 - Suppr

Suppr

超能文献

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.

作者信息

Stock-Martineau Sophie, Shepherd Frances A

机构信息

Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada.

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

出版信息

J Thorac Oncol. 2021 Nov;16(11):1793-1797. doi: 10.1016/j.jtho.2021.08.015.

DOI:10.1016/j.jtho.2021.08.015

PMID:34716003

Abstract

摘要

相似文献

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.表皮生长因子受体酪氨酸激酶抑制剂单药治疗应仍是晚期表皮生长因子受体突变型非小细胞肺癌的标准一线治疗方案。

J Thorac Oncol. 2021 Nov;16(11):1793-1797. doi: 10.1016/j.jtho.2021.08.015.

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。

Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.

EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.表皮生长因子受体联合疗法应成为晚期表皮生长因子受体突变型非小细胞肺癌新的一线标准治疗方案。

J Thorac Oncol. 2021 Nov;16(11):1788-1792. doi: 10.1016/j.jtho.2021.06.004.

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.EGFR 突变型晚期非小细胞肺癌个体化治疗进展。

Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(7):266-272. doi: 10.2183/pjab.96.020.

Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.晚期表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）患者的治疗：测序至关重要。

Pulmonology. 2019 Sep-Oct;25(5):306-309. doi: 10.1016/j.pulmoe.2019.04.005. Epub 2019 Jun 7.

Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者一线 EGFR 酪氨酸激酶抑制剂治疗后治疗模式的观察性研究。

Adv Ther. 2020 Feb;37(2):946-954. doi: 10.1007/s12325-020-01221-4. Epub 2020 Jan 18.

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.一线治疗晚期低丰度突变非小细胞肺癌（NSCLC）时，单独使用表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）或联合化疗的疗效。

Lung Cancer. 2019 Feb;128:6-12. doi: 10.1016/j.lungcan.2018.12.007. Epub 2018 Dec 6.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗

Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.

Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?贝福替尼——EGFR突变型晚期非小细胞肺癌的可行替代方案？

Lancet Respir Med. 2023 Oct;11(10):857-859. doi: 10.1016/S2213-2600(23)00216-3. Epub 2023 May 24.

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).ACTIVE 研究方案：阿帕替尼或安慰剂联合吉非替尼作为表皮生长因子受体突变型晚期非小细胞肺癌（CTONG1706）患者的一线治疗。

Cancer Commun (Lond). 2019 Nov 7;39(1):69. doi: 10.1186/s40880-019-0414-4.

引用本文的文献

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.程序性死亡受体配体1（PD-L1）通过丝裂原活化蛋白激酶（MAPK）信号通路诱导表皮生长因子受体（EGFR）突变的肺腺癌发生自噬及对EGFR酪氨酸激酶抑制剂（EGFR-TKIs）的原发性耐药。

Cell Death Dis. 2024 Aug 1;15(8):555. doi: 10.1038/s41419-024-06945-7.

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.评估伴骨转移的表皮生长因子受体突变型非小细胞肺癌：临床特征与最佳治疗策略。

Cancer Med. 2024 Apr;13(7):e7152. doi: 10.1002/cam4.7152.

Computed Tomography-derived intratumoral and peritumoral radiomics in predicting EGFR mutation in lung adenocarcinoma.基于 CT 的肿瘤内和肿瘤周围放射组学预测肺腺癌 EGFR 突变。

Radiol Med. 2023 Dec;128(12):1483-1496. doi: 10.1007/s11547-023-01722-6. Epub 2023 Sep 25.

Effects of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeted combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma.表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）靶向联合化疗对IV期肺腺癌患者免疫功能、肿瘤标志物及氧化应激的影响

Pak J Med Sci. 2023 May-Jun;39(3):742-746. doi: 10.12669/pjms.39.3.7397.

Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea.表皮生长因子受体（EGFR）突变的转移性非小细胞肺癌患者的治疗模式、临床结局及医疗资源利用情况：韩国的一项真实世界研究

Drugs Real World Outcomes. 2023 Mar;10(1):131-143. doi: 10.1007/s40801-022-00344-0. Epub 2022 Dec 2.

Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.实性成分为主的 C 期 IA 肺腺癌伴磨玻璃影：全阴性与表皮生长因子受体突变

Ann Thorac Cardiovasc Surg. 2022 Oct 20;28(5):320-328. doi: 10.5761/atcs.oa.22-00058. Epub 2022 May 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验